Ezutromid | B1248

Ezutromid is a first orally available drug for the treatment of Duchenne muscular dystrophy (DMD), a lethal, X-linked muscle wasting disease caused due to lack of dystrophin-a cytoskeleton protein. Ezutromid has shown potential as disease modifying treatment for DMD patients irrespective of their gene mutation. Ezutromid acts on utrophin modulation and has potential to slow down or stop the progression of DMD.

Ezutromid is a first orally available drug for the treatment of Duchenne muscular dystrophy (DMD), a lethal, X-linked muscle wasting disease caused due to lack of dystrophin-a cytoskeleton protein. Ezutromid has shown potential as disease modifying treatment for DMD patients irrespective of their gene mutation. Ezutromid acts on utrophin modulation and has potential to slow down or stop the progression of DMD.

B1248 | Ezutromid DataSheet

Alternate Name/Synonyms: 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole; BMN195

Appearance: Light brown solid

Formulation: N/A

CAS Number: 945531-77-1

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₁₉H₁₅NO₃S

Molecular Weight: 337.39

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO(>10 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A drug for the treatment of Duchenne muscular dystrophy (DMD),

MDL Number: N/A

PubChem CID: 25109292

SMILES: CCS(=O)(=O)C1=CC2=C(C=C1)OC(=N2)C3=CC4=CC=CC=C4C=C3

InChi: InChI=1S/C19H15NO3S/c1-2-24(21,22)16-9-10-18-17(12-16)20-19(23-18)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,2H2,1H3

InChi Key: KSGCNXAZROJSNW-UHFFFAOYSA-N